Named as Memphis Business Journal’s 2022 Class of 40 Under 40, Spicer Robertson’s motto is ‘Live in your vision, not your circumstances.’ Read how this native Memphian and founder of the DEI Collective has made her way back to the Mid-South as the chief diversity, equity and inclusion officer of
St. Jude Children’s Research Hospital.
Dr. Plummer leads new program at
St. Jude, exploring novel ways of measuring gene expression while preserving cellular organization.
By simulating molecular dynamics,
St. Jude scientists revealed how the selectivity or promiscuity of GPCR coupling relies on the location and duration of intermolecular interactions.
Investigators will present research at the annual meeting of the American Society of Hematology, with findings from the
St. Jude Lifetime cohort study.
St. Jude CEO James R. Downing MD is currently leading the $12.9 billion six-year strategic plan, the largest investment in its 60-year history to advance the study and treatment of pediatric cancer and other catastrophic diseases.
Daniel J. Blair, PhD, wins award for early-career scientists working on breakthrough discoveries in health, medicine and science.
The list is based on papers ranked in the top 1% by citations— how often a research paper is referenced by other investigators in their work.
St. Jude scientists studied the role of RNA splicing defects in Alzheimer’s disease, revealing degeneration and toxicity caused by neuron hyperexcitability.
The Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute and
St. Jude announced the largest academic collaboration of its kind.
Cellular response to low oxygen also increases fetal hemoglobin expression in adults, which could lead to novel treatments for some genetic anemias.
Cell biologist Chi-Lun Chang, PhD, was awarded a 5-year $2.7 million grant to “push the boundaries of biomedical science.”
St. Jude Children’s Research Hospital reveal that childhood cancer survivors with disadvantaged socio-demographic factors are over 7 times more likely to experience severe symptom burdens.
St. Jude scientists identified the mechanism by which Williams-Beuren Syndrome enhances the ability to discriminate between sounds as interneuron hyperexcitability in the auditory cortex.
A tool created by
St. Jude scientists may increase the safety of gene and cell therapy by finding safe places to add genes to human DNA.
St. Jude scientists found that group 3 and 4 medulloblastoma arise from the rhombic lip, knowledge that may help improve research models and therapeutic development.
St. Jude Comprehensive Cancer Center award extends its current $35 million, five-year Cancer Center Support Grant (CCSG) for an additional two years.
St. Jude department recognized for the first time with 2022 Environmental Services Department of the Year Award.
St. Jude scientists have completed the largest study of families affected by Hodgkin lymphoma and identified novel variants linked to cancer predisposition.
St. Jude Children’s Research Hospital discovered how some cancer cells survive treatment and cause cancer to recur, along with a potential way to stop the process.
St. Jude scientists sequenced the most childhood cancer samples from a single cancer type ever in a landmark study.
St. Jude Global and partners help Ukrainian children with cancer and blood disorders continue treatment, creating a model for responses to other crises.
St. Jude scientists created an LCK targeted PROTAC able to kill T-cell acute lymphoblastic leukemia cells.
St. Jude scientists developed a simple method to select for more effective cancer-destroying CAR T cells to treat T-ALL.
St. Jude scientists have created a proof-of-principle approach to improve engager T-cell therapy for difficult-to-treat acute myeloid leukemia.
The Good Manufacturing Practices (GMP) facility produces highly specialized biopharmaceuticals and other biological products for the hospital’s clinics.
St. Jude scientists created a way to identify childhood cancer patients at diagnosis who are at the highest risk for developing severe obesity as adults.
St. Jude found an Achilles’ heel in rhabdomyosarcoma driven by a gene fusion which revealed a promising treatment approach in the lab.
Six-year plan will now commit $12.9 billion to support 2,300 jobs, among other priorities.
St. Jude High School and College Research Immersion Program introduces science to a diverse group of students
St. Jude scientists have shown how the presence or absence of primary cilia contribute to specific types of the most common malignant childhood brain tumor.
St. Jude scientists developed a method that could improve CAR T-cell therapies by identifying the early cells that become effective at killing cancer.
Tosh is the first
St. Jude patient to reach this milestone and was recognized at institution’s 60th anniversary celebration
New collaboration with multiple organizations is part of national effort to provide equity in STEM education.
St. Jude immunologists identified proteins that help decide T cell fate and used the finding to improve CAR-T cell therapy in a solid tumor model.
St. Jude Children’s Research Hospital recognized among hospitals delivering exceptionally high-quality care
St. Jude scientists identified a genetic difference in childhood cancer survivors treated with chemotherapy that predisposes them to heart problems as adults.
St. Jude scientists are studying how the temperature at which protein structures are captured can create "artifacts," – errors that cause misleading results.
Learn best practices and hear insights from
St. Jude oncologists, psychologists and scientists at the annual gathering of clinical oncology experts.
St. Jude scientists have a new understanding of the pathways that contribute to this gene silencing.
St. Jude scientists uncovered how one type of T cell creates two genetically identical, but functionally different, daughter cells.
This the first time researchers have identified the mechanism for closed-state inactivation. These approaches could be applied to other ion channels.
St. Jude scientists identified ZBP1 as a key contributor to the inflammatory cell death that drives morbidity and mortality in COVID-19 patients.
St. Jude scientists will discuss research on cellular therapies for pediatric cancer and more at the annual meeting.
Big data can cause big problems in rare disease genetics research. Scientists at
St. Jude created a systematic solution to find the inherited genes contributing to rare disease.
St. Jude demonstrate the role of chromatin regulation in cancer’s resistance to EZH2 inhibitors and offer a way to make treatment more effective.
The team looked at a poorly understood form of chronic leukemia, CLPD-NK. The results led the researchers to create a new model of cancer development.
St. Jude are studying antimicrobial compounds called argyrins. Argyrins have shown some success against a bacterium called Pseudomonas aeruginosa.
RMS is the most common soft tissue sarcoma in children. When it recurs after therapy, the survival rate is only 30%.
St. Jude scientists and their Columbia University collaborators reveal how GPCR signaling is regulated with implications for drug development.
St. Jude scientists have found the first known example of a promoter ‘donation’ event from a retrotransposon causing a highly malignant childhood brain cancer.
Dr. Taylor steps into the role during a pivotal time of growth for
St. Jude, as its scientific enterprise will significantly expand.
Dr. Amar Gajjar becomes the seventh
St. Jude Children’s Research Hospital investigator to receive the Pediatric Oncology Award
The AACR also honored the
St. Jude scientist for her contributions to advancing women in science.
St. Jude researchers are recognized by the American Society of Pediatric Hematology/Oncology for their expertise and career achievements
St. Jude scientists have studied how vaccination before and after primary infections affect the immune response.
St. Jude Children’s Research Hospital will participate in the annual gathering of a premier professional society for the cancer research community.
Four more Ukrainian children with cancer and their 11 family members arrived at
St. Jude Children’s Research Hospital in Memphis, Tennessee.
St. Jude continues to help move hundreds of Ukrainian children with cancer to safety so they can continue treatment.
Dr. Downing is honored for his outstanding contributions and innovations in cancer research.
St. Jude Children’s Research Hospital findings lay the groundwork for identifying pediatric cancer survivors at higher risk of accelerated aging and chronic diseases.
St. Jude scientists have found a clue as to why our immune systems do not target virus components that all flu strains share.
PEWS are not widely used in hospitals with limited resources. To understand why, scientists at
St. Jude conducted a study.
Private, comfortable space in newly designed airport concourse will be staffed by
St. Jude employees.
On Saturday, the Foundation’s building in Bocheniec, now officially named the Unicorn Marian Wilemski Clinic, welcomed the first group of Ukrainian children and their families. Read more about this ongoing effort.
Emphasizing the need for HPV vaccination, the campaign launches March 4, 2022, International HPV Awareness Day.
St. Jude scientists have found a previously overlooked mutation in a subtype of pediatric leukemia that has implications for identifying high-risk patients.
The hospital relocates 500 administrative employees to the temporary workspace during the construction phase of its six-year strategic plan.
St. Jude scientists blocked development of acute lymphoblastic leukemia in mice with a genetic mutation that increases the risk of childhood cancer.
Diamond jubilee events are planned nationwide for supporters to honor
St. Jude visionaries, recognize expanding global impact of scientific, medical achievements
St. Jude scientists have shown that the active immune system in young hosts may actually work against cancer immunotherapies by exhausting T cells.
St. Jude have revealed how an inherited genetic variant turns on an oncogene, increasing the risk of developing childhood leukemia. Published in Nature Genetics.
St. Jude scientists created an immunotherapeutic strategy for a type of pediatric leukemia using CAR T cells that target a tumor-specific antigen.
St. Jude scientists show that addressing racial disparities in acute lymphoblastic leukemia should include considering how genetic ancestry affects biology and prognosis.
St. Jude study also suggests that prior immunity to common cold coronaviruses does not protect against SARS-CoV-2 infection.
St. Jude identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer.
St. Jude have captured the structure of autoactivated BAK, a key protein for triggering apoptosis in cancer cells.